Steps Towards Establishing a New Community-led Initiative Focusing on Immune Challenges

The CLL Advocates Network (CLLAN) is proud to announce that it is setting up a new community-led initiative to address the immune challenges people living with chronic lymphocytic leukaemia (CLL) face.

We aim to build on the insights from our 2023 white paper, “Compromised: Uncovering the Immune-Related Challenges Facing People with Chronic Lymphocytic Leukaemia”  funded by AstraZeneca, and establish a new community-led initiative that will translate these findings into tangible improvements for people living with CLL.

In July, the CLL Advocates Network (CLLAN), with agency support, hosted two virtual workshops to shape a new community-led initiative to address the immune challenges faced by people living with Chronic Lymphocytic Leukaemia (CLL).

This exciting initiative, marks a pivotal shift in focus, shining a spotlight on the immune challenges experienced by CLL patients.

A gathering of 32 experts from 19 countries across the globe, including leading voices from the clinical and patient advocacy communities, came together to join this unique and ground-breaking initiative. The workshops were kindly supported by Astra Zeneca and Takeda, setting the stage for a multi-sponsorship funding approach moving forward.

During the workshops, participants engaged in rich discussions about various policy and advocacy priorities for the future. Now, they are ready to embark on a prioritisation exercise to identify key activities for the newly formed CLL Immune Challenges (CLL IC) Taskforce.

Stay tuned for more information on the launch of the CLL IC Taskforce and the exciting initiatives its members will lead. If you’re interested in joining as an industry partner or member, we’d love to hear from you!

Together, we can overcome immune challenges and enhance the quality of life for all people affected by CLL